×

Cortice Biosciences Announces Upcoming Presentations at the 2014 Cell Symposia for Translational Neuroscience and the Annual Meeting of the Society for Neuroscience

NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from preclinical studies evaluating the activity of pipeline drug candidates CRT 001 and TPI 287 in models of neurodegenerative diseases will be presented at the 2014 Cell Symposia for Translational Neuroscience in Arlington, VA and the Annual Meeting of the Society for Neuroscience in Washington, D.C. Presentations include:

Title: Targeting beta1-adrenergic pathway as a novel approach to treat Alzheimer's disease

Date: Friday, November 14
Time: 1:00 – 2:30 PM ET
Place: 2014 Cell Symposia for Translational Neuroscience
Poster: P2.59
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Title: Role of beta1-adrenergic signaling in Alzheimer's disease (AD)

Date: Wednesday, November 19
Time: 8:00 AM - 12:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 792.14/G4
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Both presentations will include results demonstrating the ability of CRT 001 (xamoterol fumarate) to modulate cognitive behavior in animal models of Alzheimer's disease. Cortice plans to advance CRT 001 in clinical development in 2015 for treatment of one or more diseases associated with cognitive impairment.

Title: Effects of TPI 287, a novel taxoid, on a transgenic mouse model of Alzheimer's disease

Date: Wednesday, November 19
Time: 1:00 - 5:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 691.12/C48
Presenter: Erwin Defensor, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Results demonstrating the ability of TPI 287, a brain-penetrable microtubule stabilizing agent, to improve cognitive performance in a mouse model of tauopathies will be presented. TPI 287 is currently being evaluated in Phase 1 clinical trials as a potential treatment for the orphan disease tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), as well as Alzheimer's disease.

About TPI 287

TPI 287 is a taxoid that binds to and stabilizes the assembly of microtubules similarly to the taxanes, paclitaxel and docetaxel. Compared with these other taxanes, TPI 287 has the distinct advantage of being able to readily penetrate the blood-brain barrier. Microtubule stabilization by TPI 287 in the brain may have potential as treatment of neurodegenerative diseases known as tauopathies that are associated with dysfunctional tau protein and defective microtubule architecture. Accordingly, TPI 287 is being developed for the treatment of the tauopathies progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Alzheimer's disease (AD). As an anti-cancer agent designed to inhibit cellular division and growth, TPI 287 is also being evaluated for the treatment of glioblastoma and secondary brain metastases.

About CRT 001

CRT 001 is a partial agonist of the beta1 adrenergic receptor, a family member of G-protein coupled receptors that control noradrenergic (NA) signaling, which is critical for learning and memory formation in mammals. NA signaling is also significantly disrupted in diseases associated with dementia, including Alzheimer's disease. CRT 001 was previously marketed in select European countries as xamoterol (Corwin) for the treatment of mild-to-moderate heart failure, and has been shown to be safe and well tolerated in over 70 published clinical trials that enrolled over 3,500 subjects. Based on this attractive clinical profile and highly compelling preclinical results, Cortice intends to develop CRT 001 for the treatment of diseases associated with cognitive impairment, which include Alzheimer's disease, Down syndrome, and several related orphan indications.

About Cortice Biosciences

Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Cortice Biosciences, which can be identified by the use of terminology such as "will," "would," "should," "expects," "anticipates," "intends," "plans," "believes," "may," "estimates," "predicts," "projects," or similar expressions intended to identify such statements. These statements reflect the current views of Cortice with respect to future events, are based on assumptions, and subject to risks and uncertainties.

CONTACT: Cortice Biosciences, Inc. 646-747-9090 info@corticebio.com

Source: Cortice Biosciences